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1. Introduction
Haemostasis  prevents  leaks  or  obstructions  within  the  blood  vessels  following  three
interrelated  sequences:  formation  of  the  haemostatic  plug,  platelet  consolidation  and
dissolution of fibrin clot by the fibrinolytic system (Juhan-Vague and Hans 2003; Van Cott
and Laposata 2001; Vasse 2008). Coagulation factors circulate in the blood as proenzymes
until they are activated by vascular damage (Lane et al. 2005; Owens and Mackman 2010).
These enzymes amplified and disseminated the sequence and then are stopped by natural
inhibitors (Mulder et al. 2010; Middeldorp 2011) and the fibrinolytic system (Greenberg and
Orthner 1999; Levi et al. 2012). Cellular phospholipids make the process much more efficient
(Hoffman 2003; Gentry 2004; Rivera et al. 2009).Activated Factor XIIIa stabilizes the polymer
(Sidelmann et al. 2000; Greenberg and Lai 2003; Muszbek et al. 2011). Plasminogen (Plg) is
the key in thrombus lysis;  and is synthesized in mammals principally by the liver (Staf‐
ford 1964; Degen 2001; Zhang et al. 2002; Zorio et al. 2008). Natural Plg activators are: tissue
plasminogen activator  (tPA) and urokinase (uPA) (Fleming and Melzig 2012);  streptoki‐
nase (SK) acts as in an exogenous path (Sazonova et al. 2009). Free Plm is very active and
degrades other proteins,  such as complement,  fibrinogen (Fbg),  factors II,  V and VIII  or
activates metallo-proteases involved in tissue remodeling by degradation of cellular matrix
(Collen 2001; Parfyonova et al. 2002; Dewyer et al. 2007).The main inhibitors of Plm are the
alpha2 plasmin inhibitor (α2PI) (Menoud et al. 1996; Fraser et al. 2011) and Plasminogen
activator inhibitor type 1 (PAI-1) (Declerk et al. 1998; Vaughan 2005). Thrombin activata‐
ble fibrinolysis inhibitor (TAFI) is a link between the two systems, it is activated by thrombin
generated during coagulation, and suppresses fibrinolysis (Marx 2004; Hilmayer et al. 2006;
Milijic et al. 2010).
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2. Selection of animal model in fibrinolysis, a challenge
There is a growing homology in the components of the fibrinolytic system along zoological
evolution. Fibrinolysis is present in all vertebrates but invertebrates generally only have
clumping of blood corpuscles (Withers 1992). Vertebrates factors involved in coagulation and
fibrinolysis have evolved from common ancestral proteins and fibrinolytic ones seem to be
related to digestive proteolytic enzymes used by rudimentary microorganisms to be released
and disseminated, avoiding the host´s nonspecific defense and immunity response (Patthy
1990; Gladysheva et al, 2003; Opal and Esmon 2003; Levi et al. 2012).
Insects have rich sources of pharmacological active substances that may have medical value:
The venom of Lonomia oblique caterpillar may induce a hemorrhagic syndrome in humans, and
blood incoagulability in laboratory animals (Prezoto et al. 2002). Bee venom of Bombus
ignites contains a Kunitz type serine protease inhibitor (Bi-KTI) that acts as an antifibrinolytic
agent inhibiting plasmin (Choo et al 2012). In nature, there are many animals adapted to a diet
of fresh blood, and they had to evolve mechanisms to control their host coagulation processes,
to maintain the blood in a fluid state during intake and subsequent digestion (Tanaka-Azevedo
et al 2010). A variety of coagulation inhibitors have been isolated from blood sucking animals
such as ticks (Jacobs et al 1990; Waxman et al 1990), leeches (Sawyer 1986, 1991), hookworms
(Cappello et al 1995) and bats (Gardell et al 1991).
Very little is known about the fibrinolytic system and its component concentrations in animals
and the relevance of these models for human health is questioned due to many reasons:
interspecies differences (Siller-Matula et al. 2008; Ralph and Brainard 2012), lack of reliable
results (Vap et al. 2012), use of diagnostic equipment designed only for human care, inadequate
relationship of test reagent to clotting factor concentration (Ravanat et al. 1995; Jagadeeswaran
and Sheehan 1999; Kubalek et al. 2002, Münster et al. 2002; Gentry 2004; Weir-M et al. 2004).
Also, anatomical features of the animal chosen can make it really difficult to obtain good
quality blood samples (Saito et al. 1976; Meinkoth and Allison 2007). For example, vessel size
and blood flow are important determinants of vascular function when mouse model is used
for human research of aorta (Fay et al 2007).
3. Objective of this chapter
In this chapter we summarize the actual knowledge about fibrinolytic assays among different
animal species and we compare these findings with healthy adult human beings.
4. Fibrinolytic parameters
A  review  of  laboratory  tests  was  conducted  in  a  phylogenetic  order:  fish,  amphibians,
reptiles, birds and mammals. It was designed to assess the fibrinolytic system in its various
stages:  global  (whole  blood  lysis  time  WBLT,  whole  blood  diluted  lysis  time  WDLT,
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euglobulin  lysis  time ELT),  specific  (Plg,  PAI-1,  tPA,  α2PI  and the  thrombin-activatable
fibrinolysis inhibitor TAFI) and degradation products generated from the degradation of
fibrinogen  /  fibrin  FDP,  D  Dimer  DD,  and  Plm-α2PI,  tPA-PAI-1,  uPA-PAI-1  complexes
(Blanco 2003; Urano and Suzuki 2011).
The results of these assays are summarized in Tables 1, 2, 3, 4, 5, 6, 7, 8, 9 and 10 (Tentoni et al,
2010).
In fishes the information is insufficient (Tables 1 and 2). WBLT is undetectable in lamprey
and black fish,  while lysis is  fast  in dog fish.  The genes encoded for Plg and tPA were
identified in the blowfish Fugu rubripes (Jiang and Doolittle 2003). Rats with diets based on
fish  oil  decrease  the  fibrinolytic  activity  due  to  an  increase  of  PAI-1  (Sano et  al.  2003),
whereas dietary supplementation with fish protein increases fibrinolysis by increasing tPA
in blood (Murata et al. 2004).
In amphibians (Tables 1 to 3), the marine toad Bufo marinus and the tree frog Hyla caerula show
spontaneous WBLT (Hackett and Lapage 1961, Hackett and Hann 1964), while it does not occur
in the common frog Rana temporaria, leopard frog Rana pipiens or the clawed toad Xenopuslae‐
vis(Table 2),but can be induced if possible inhibitors are removed, which suggests a large
concentration of antifibrinolytic agents. The existence of a protein similar to Plg in Rana
tigrina and Xenopus laevis is explained by the fibrinolysis produced after the addition of uPA
(Srivastava et al. 1981).
There is no evidence of a fibrinolytic system in reptiles, lizards (Trachydosaurus rugosus
rugosus, Tiliqua scincoides, Amphibolorus barbatus, Varanus acanthrus, Iguana iguana),
turtles (Chelodina longicollis), crocodiles (Crocodylus porosus) or pitons (Liasis spp, Morelia
spp) (Tables 1 and 10). A strong circulating antithrombin protects these vertebrates from
intravascular thrombosis (Hackett and Hann 1964; Kubalek et al. 2002), however low concen‐
trations of α2PI were detected in the circulation of the snake Bitis arietans using a chromogenic
method (Table 10).
Snake venoms are mixtures of many peptides which affect the blood coagulation and fibri‐
nolysis pathways such as Plg activators (Kini 2005; Miller et al 2009) and fibrinogen degrada‐
tors (Meyer 2000). Recently a non hemorrhagic metalloproteinase (BleucMP) was purified from
Bothrops leucurus snake venom by two chromatographic steps procedure on DEAE-Sephadex
A-25, which has an efficient proteolytic action over fibrinogen (Sérgio et al 2011).
Birds are deficient in Factors XI and XII so the clotting times exceeding 70 minutes (Wartelle
1957; Soulier et al. 1959, Bigland 1964). Fibrinolysis can be activated with the saliva of the vampire
Diaemus youngui (Cartwright and Hawkye 1969), but not with SK (Cliffton and Cannamela
1951). Plg concentration in quails is indetectable due the chromogenic assay is activated with
SK instead of uPA. Vultures have the highest reported value DD concentration among the
animals with reduced levels of Fbg and clotting factors, remaining a disseminated intravascu‐
lar coagulation in man, with the advantage of being easily reversible (Weir-M et al. 2004).
The WDLT in the Halichoerus grypus is lower than in humans (Table 3), suggesting the existence
of an active fibrinolytic system.The Plg activity in Balaenoptera borealisis cannot be activated by




FDP was undetectable in the Mirounga angustirostris elephant seal (Table 1 and 6).
Plg activators similar to tPA were discovered in the South American vampire bat´s Desmodus
rotundus saliva (Verstraete 1995) and they all need fibrin as a cofactor (Schleuning et al.
1992).These activators do not degrade Fbg, or cause neuronal damage such as tPA does
(Grandjean et al. 2004) and also have a prolonged plasma half-life (Zavalova et al. 2002).
In dogs (Tables 1, 3, 4, 5, 6, 7 and 10), except for the Plg when it is measured by activation with
SK, the values of all the fibrinolytic assays are quite similar to the values in humans, as reported
by Wohl et al. (1983).
In cats (Tables 1, 3, 5, 9 and 10) there is a marked difference in functional PAI-1 activity when
compared to man, and its Plg cannot be activated with tPA but with uPA (Welles 1996).
In studied rodents, the fibrinolytic system is quite similar to that in humans, but Plg is poorly
activated with SK; Plg, tPA, uPA and PAI-1 have been described in Mus musculus mouse
(Tables 1, 7 and 8), the first two having high sequence homology with their human counterpart
(Poplis and Castellino 2002). Interesting enough, PAI-1 deficient mice present a mild hyperfi‐
brinolytic state in adulthood, whereas Plg deficiency predisposes to severe thrombosis
(Eitzman et al. 2000; Mackman 2005). The main inhibitors of fibrinolysis in mice are α2PI and
TAFI (Marx et al. 2000). In rodent capybara Hydrochaeris hydrochaeris (Tables 1 and 5), Plg
cannot be activated even with 500 U/mL of SK (Leitao et al, 2000).
Rat (Tables 1, 3, 4, 5, 7, 8, 9 and 10), guinea pigs (Tables 4, 5 and 10) and rabbits (Tables 1, 3, 4,
5, 7, 9 y 10) are the most employed animal models in fibrinolytic research.
Plg cannot be activated with SK in cattle (Tables 1, 5, 6 and 10), pigs (Tables 1, 5, 7 and 10) and
sheep (Tables 5, 7 and 10), (Cliffton and Cannamella 1953; Korninger and Colleen 1981; Wohl
et al 1983; Zhang et al 2012). Horses (Tables 1, 5, 6, 7, 9 and 10) have higher levels of functional
PAI-1 and α2PI when compared to humans (Barton et al. 1998). The fibrinolytic activity in
llama is similar to that of horses and other domestic species (Morin et al 1995).
In armadillos Chaetophractus villosus our research group found prolonged WBLT and WDLT
with PAI-1 functional activity four times greater than in man; this high concentration of
inhibitor can be successfully removed with the ELT technique, despite the anticoagulant used
(citrate/oxalate). The α2PI concentration is similar to that measured in humans. DD was
undetectable in the immunological test (Tentoni et al., 2008). Nevertheless we found FXIII
activity in this mammal, with a range from 32 to 78 percent (%) in relation to the calibration
curve obtained with a pool of healthy humans platelets poor plasma using Berichrom chro‐
mogenix assay (Dade Behring). The fibrin plug was resistant to urea 5M for more than 36 hours;
its coagulation factors depend on the vitamin K cycle because the oral administration of 0.28
mg/kg/day of acenocumarol increased baseline values of Prothrombin time PT (p<0.01) and
activated Partial Thromboplastin time aPTT (p<0.05). When PTT-LA reagent is used in aPTT
assays in armadillos, the typical shortened values of this specie (20 seconds) increases (26-30
seconds) (Tentoni et al., unpublished), as observed in pigs by Velik-Salchner et al. (2006).
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Species Fbg (mg/dL) Author
human 188 - 381 Williams et al, 2005
armadilloa 211 - 333 Casanave et al, 2006
armadilloa´ 258 - 380 Tentoni et al, 2008
whaleb 147 Saito et al, 1976
iguanac 420 - 440 Kubalek et al, 2002
catd 50 - 165 O´Rourke et al, 1982
cat 150 - 400 Herring and McMichael, 2012
eaglee 80 - 160 García-Montijano et al, 2002
frogf 590 - 990 Coppo et al, 2005
dolphing 269 - 417 Tibbs et al, 2005
mouseh 200 - 260 Tsakiris et al, 1999
dog 141 - 227 Mischke et al, 2000
dog 179. - 329 Machida et al, 2010
dog 150 - 400 Herring and McMichael, 2012
rat 168 - 192 Honda et al, 2008
japanese quaili 140 - 260 Belleville et al, 1982
pigj 181 - 534 Velik-Salchner et al, 2006
pig 130 - 170 Schöchl et al, 2011
rabbitk 257 - 286 Marval et al, 1992
cowl 125 - 697 Heuwieser et al, 1989
sheep 178 - 215 Wilhelmi et al, 2012
horsem 78 - 156 Barton et al, 1998
monkeyn 119 - 239 Suzuki et al, 1977
elephant sealo 50 - 162 Gulland et al, 1996
capybarap 124 Leitâo et al, 1999
ostrichq 172 - 356 Frost et al, 1999
caimanr 430 - 1500 Arocha-Piñango et al, 1982.
marine fishs 220 - 280 Pavlidis et al, 1999
asian elephantt 412 - 510 Gentry et al, 1996
vultureu < 20 Weir-M et al, 2004
llamav 140 - 300 Morin et al, 1995
A Chaetophractus villosus (n:20); a´ (n:24); b Balaenoptera borealis (n:1); c Iguana iguana (n:26); d (n:21); e Aquila adal‐
berti (n:12); f Rana catesbeiana (n:302); g Tursiops truncatus (n:17); h Mus musculus; i Coturnix coturnix japonica ; j(n:
80); k New Zealand rabbits (n:102); l (n:90); m foals (n:53); n Macaca fuscata (n:52); o Mirounga angustirostris (n:19); p
Hydrochaeris hydrochaeris (n:2); q Struthio camelus (n:30); r Caiman crocodilus; s Dentex dentex; t Elephas maximus; u
Coragyps atratus (n:2); v (n: 46 adult females); < less than.




Species WBLT (hours) Author
human "/> 24 Conard, 1976
lampreya nd Hawkey, 1971
black fishb nd Hawkey, 1971
common frogc nd
Blofield, 1965leopard frogd nd
clawed toade nd
domestic birds nd Niewiarowski & Latallo, 1959
dogfishf 2 – 4 Hawkey, 1971Doolittle & Surgernor, 1962
japanese quailg "/> 72 Belleville et al, 1982
armadillo "/> 72 Tentoni et al, 2008
a Petromyzon marinus; b Tautoga onitis; c Rana temporaria; d Rana pipiens; e Xenopus lavéis; f Mustelus canis; g Co‐
turnix coturnix japonica (n:10 adult males); nd: not detectable; > more than.
Table 2. Whole blood lysis time (WBLT) values in different vertebrates
Species WDLT (hours) Author
human > 20 Fearnley et al, 1957
tiger froga > 48 Srivastava et al, 1981
sealb 5.9 – 8.5 Lohman et al, 1998
dogc > 20
Hedlin et al, 1972ratd > 20
rabbite > 20
rabbitf > 30 Hassett et al, 1986
catg nd Welles et al, 1994
armadillo > 72 Tentoni et al, 2008
nd: not detectable; a Rana tigrina (n:6) measured at 4 and 37ºC; at 22ºC WDLT range was 31.5-45.3 hours; b Halichoe‐
rus grypus (n:2, both females), before immersion; c (n:3); d (n:6); e (n:4); f New Zealand male rabbits (n:4); g (n:15); >
more than.
Table 3. Whole blood diluted lysis time (WDLT) values in different vertebrates
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Species ELT (minutes) Author
human "/> 120 Kowalski et al, 1959
armadilloa 15.4 – 45.6 Bermúdez, 2003
armadillo a´ 24.5 - 93 Tentoni et al, 2008
tiger frogb nd Srivastava et al, 1981
japanese quailc nd Belleville et al, 1982
dog 21 - 109 Hedlin et al, 1972
guinea pigd < 90 Kaspareit et al, 1988
rabbit 270 - 450 Hassett et al, 1986
monkeye 240 Suzuki et al, 1977
vulturef nd Weir-M et al, 2004
rat 105 - 145 Groza et al, 1988
a Chaetophractus villosus using citrated plasma (n:20, 10 females and 10 males); a´ using oxalated plasma; b Rana ti‐
grina (n:6); c Coturnix coturnix japonica (n:10 young males); d Cavia porcellus (n:45); e Macaca fuscata; f Coragyps atra‐
tus (n:2); nd: not detectable; > more than; < less than.
Table 4. Euglobulin lysis time (ELT) values in different vertebrates
Species Plg (%) Author
human 80 - 120 Perkins, 1999
japanese quaila 0 Belleville et al, 1982
dog 102 - 115 # Lanevschi et al, 1996b
dog 3,2 - 4,4 Karges et al, 1994
cat 50 - 200 O´Rourke et al, 1982
cat 94 - 122
Karges et al, 1994
rat 6 - 14
guinea pigb 0.4 – 6.1
rabbit 2
rabbit 147 - 217 # Marval et al, 1992
rabbit 84 - 108 # Hassett et al, 1986
sheep 0.7 – 1.5





Species Plg (%) Author
monkeyc 24 - 39
monkeyd 164 # Suzuki et al, 1977
capybarae 0 Leitâo et al, 2000
pig 2.1 – 5.2 Karges et al, 1994
pig 0 Hahn et al, 1996
horsef 66.5 – 98.1 Barton et al, 1998
whaleg 112 # Saito et al, 1976
armadillo 28 - 40 Tentoni et al, 2008
Results are expressed as percent for Plg activity in relation to the calibration curve obtained with a pool of healthy
humans platelets poor plasma, using a chromogenix assay after activation with SK.
a Coturnix coturnix japonica (n:10 young males); b Cavia porcellus; c Macaca fascicularis; d Macaca fuscata; e Hydro‐
chaeris hydrochaeris, it was impossible to activate its Plg with 500 U/mL of SK; f neonatal foals, Plg calibration curve
was performed using equine pooled plasma; g Balaenoptera borealis (n:1); # Plg measured using uPAas activator.
Table 5. Plasminogen (Plg) activity values in different vertebrates
Species FDP (μg/mL) Author
human < 10 Amiral et al, 1990
dog < 5 Boisvert et al, 2001
dog < 5 Stokol, 2003
dog < 5 Griffin et al, 2003
dog 0 – 1.18 Machida et al, 2010
dog < 10 Herring & McMichael, 2012
cat < 10 Herring & McMichael, 2012
horse 5.5 – 10.9 Barton et al, 1998
horse < 10 Stokol et al, 2005
elephant seala 0 Gulland et al, 1996
dolphinb < 10 Tibbs et al, 2005
cow < 5 Irmak & Turgut, 2005
armadillo 0 - 10 Tentoni et al, 2008
A Mirounga angustirostris; b Tursiops truncatus (n: 12); < less than.
Table 6. Fibrin fibrinogen degradation products (FDP) concentration values in different mamals
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Species DD (μg/mL) Author
human < 0.50 Estève et al, 1996
dog 0.08 – 0.39 Stokol et al, 2000b
dog 0.02 – 0.28 Caldin et al, 2000
dog < 0.25 Nelson, 2005
dog < 0.25 Herring & McMichael, 2012
cat < 0.25 Herring & McMichael, 2012
rat 0.18 Asakura et al, 2002
rat < 0.02






mouse 0 Tsakiris et al, 1999
pig 0 Roussi et al, 1996
pig < 0.01 Schöchl et al, 2011
horseb 0.46 – 0.92 Monreal et al, 2000
horse 0 – 0.91 Machida et al, 2010
horse < 0.50 Stokol et al, 2005
ostrich 0.25 Frost et al, 1999
vulture "/> 1 Weir-M et al, 2004
armadillo nd Tentoni et al, 2008
dolphin < 0.50 Tibbs et al, 2005
A Papio papio; b (n: 30); nd: not detectable; < less than; > more than.
Table 7. D Dimer (DD) concentration values in different vertebrates.
Species PAI-1 immunologic(ng/mL) Author
human 4 – 43 Declerck et al, 1988
mousea 1.3 – 2.5 Tsakiris et al, 1999
mouse 1 – 2 Matsuo et al, 2007




Species PAI-1 immunologic(ng/mL) Author
pigb 5.6 – 9.0 Schöchl et al, 2011
armadillo 1.0 – 2.2 Tentoni et al, 2008
rat 3.9 Nieuwenhuys et al, 1998
A Mus musculus (n: 160); b measured with Porcine PAI-1 Activity Assay
Table 8. Immunological Plasminogen activator inhibitor type 1 (PAI-1) concentration in different mammals
Species PAI-1functional (U/mL) Author
human < 10 Van Cott & Laposata, 2001
cat 0 Welles, 1996
rabbit 0.06 – 0.16 Hassett et al, 1986
horse 19.6 – 42.2 Barton et al, 1998
armadillo 24.8 – 37.7 Tentoni et al, 2008
rat 1.0 Nobukata et al, 2000
rat 4.9 – 7.4 Emeis et al, 1992
Results are expressed as units of PAI-1 present in plasma in relation to the calibration curve obtained with a commercial
standard when using immunological test; < less than
Table 9. Functional Plasminogen activator inhibitor type 1 (PAI-1) concentration in different mammals
Species α2PI (%) Author
Human 70 - 130 Teger-Nilsson et al, 1977
japanese quaila 65 - 85 Belleville et al, 1982
ostrichb 115.6




whaled 50 Saito et al, 1976
dog 96 - 103 Lanevschi et al, 1996b
dog 92 - 94
Karges et al, 1994cat 70 - 86
rat 118 - 138
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Species α2PI (%) Author
guinea pige 91 - 101
sheep 90 - 109
pig 63 - 104
monkeyf 82 - 99
rabbit 91 - 108
rabbit 66 - 92 Hassett et al, 1986
pig 87 - 127 Hahn et al, 1996
rat 120 Nobukata et al, 2000
horse 154 - 240 Barton et al, 1998
cow 80 - 94 Daugschies et al, 1998
armadillo 72 - 101 Tentoni et al, 2008
Results are expressed as percent for α2PI activity in relation to the calibration curve obtained with a pool of healthy humans
platelets poor plasma, using a chromogenix assay after activation with an excess of Plm.
a Coturnix coturnix japonica; b Struthio camelus; c Bitis arietans; d Balaenoptera borealis (n:1); e Cavia porcellus; f Macaca
fascicularis.
Table 10. alpha2 plasmin inhibitor activity (α2PI) in different vertebrates
5. Conclusions
The information summarized in this chapter helps the choice of appropriate animal experi‐
mental models for studying fibrinolysis and the correct extrapolation of animal results toward
humans. Previous work from our laboratory, has identified the choice of the armadillo as an
animal model because it adapts well to captivity conditions, endures repeated blood sampling,
shows excellent tolerance to cardiac puncture and recovers quickly from anaesthesia
(Bermúdez et al. 2004; Casanave et al. 2005; 2006). Chaetophractus villosus has a hypercoagulable
and hypofibrinolytic profile (Tentoni et al., 2008) as pigs, which are frequently used as an
animal model in human research. Finally, the study of animals’ haemostatic mechanisms is
important in the field of zoology, for the advancement of scientific knowledge and in biome‐
dicine, helping to select a suitable experimental animal model.
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